title: Chinese herb derived-Rocaglamide A is a potent inhibitor of pancreatic cancer cells.
abstract: Pancreatic cancer ranks No.1 in mortality rate worldwide. This study aims to identify the novel anti-pancreatic cancer drugs. Human pancreatic carcinoma cell lines were purchased from ATCC. CPE-based screening assay was used to examine the cell viability. Patient derived tumor xenografts in SCID mice was established. The Caspase-3 and 7 activities were measured using the Caspase Glo 3/7 Assay kit. Soft agar colony formation assay was used to evaluate the colony formation. Wound healing assay was employed to determine the cell migration. We screened a Chinese herbal product library and found three "hits" that kill cancer cells at nanomolar to micromolar concentrations. One of these compounds, rocaglamide, was found to be potent inhibitors of a wide spectrum of pancreatic cancer cell lines. Furthermore, Rocaglamide reduced the tumor size in a patient-derived pancreatic cancer xenograft mouse model without noticeable toxicity in vivo. Rocaglamide also inhibits pancreatic cancer cell migration and invasion. In conclusion, these data support that Rocaglamide may be a promising anti-pancreatic cancer drug.
authors.affiliation: Department of General Surgery, Xiangya Hospital, Central South UniversityXiangya 410008, China; Department of General Surgery, Hainan Province People's HospitalHaikou 570311, China.
authors.forename: Baochun
authors.initials: B
authors.lastname: Wang
authors.affiliation: Department of General Surgery, Xiangya Hospital, Central South University Xiangya 410008, China.
authors.forename: Yixiong
authors.initials: Y
authors.lastname: Li
authors.affiliation: Department of General Surgery, Xiangya Hospital, Central South University Xiangya 410008, China.
authors.forename: Fengbo
authors.initials: F
authors.lastname: Tan
authors.affiliation: Department of General Surgery, Hainan Province People's Hospital Haikou 570311, China.
authors.forename: Zhanxiang
authors.initials: Z
authors.lastname: Xiao
keywords: Pancreatic cancer; Rocaglamide; cell death; high throughput screening